A Considerable Setback For Cancer Trials Because Of COVID-19, IQVIA/CRI Survey Finds
Patient enrollment in clinical trials for cancer drugs was "severely" affected by the COVID-19 pandemic, according to a report published in Nature Reviews Drug Discovery.
You may also be interested in...
Rather than expose patients and others to SARS-CoV-2, Provention opted to pause a Phase III type 1 diabetes trial. Addex and Iveric have since delayed trial initiations and more studies are likely to be impacted as coronavirus concerns mount.
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.